Welcome to our dedicated page for Q/C TECHNOLOGIES SEC filings (Ticker: TNFA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Q/C TECHNOLOGIES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Q/C TECHNOLOGIES's regulatory disclosures and financial reporting.
TNF Pharmaceuticals (TNFA) reported significant operating losses and financing activity for the six months ended June 30, 2025. The company recorded a net loss of $19,365,689 (six months) and $2,920,938 (three months) with research and development expenses of $2,418,985 (six months) and $873,472 (three months). Preferred stock dividends materially reduced results, totaling $1,789,865 (six months) and $976,369 (three months).
The filing discloses heavy financing through multiple preferred series and warrant issuances, conversions and anti-dilution adjustments (Series F, F-1, G and D), and large share issuances during the period. The company reports negative operating cash flows and states substantial doubt about its ability to continue as a going concern without additional capital. The company also received a Nasdaq notice regarding a minimum bid price deficiency and has a compliance period to regain the $1.00 minimum bid requirement.
TNF Pharmaceuticals, Inc. filed a notice that it will not submit its Quarterly Report on Form 10-Q for the six months ended June 30, 2025 on time. The company states it needs additional time to complete and finalize the financial statements required for this report. It expects to file the Form 10-Q on or before the fifth calendar day after the original due date, relying on the automatic extension provided under SEC Rule 12b-25.